ConvaTec Group PLC (LON:CTEC) Receives GBX 320.33 Consensus Price Target from Analysts

Shares of ConvaTec Group PLC (LON:CTEC) have been given a consensus recommendation of “Buy” by the six brokerages that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is GBX 320.33.

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. reissued an “overweight” rating on shares of ConvaTec Group in a research note on Friday, November 14th. UBS Group reissued a “buy” rating and issued a GBX 375 price target on shares of ConvaTec Group in a report on Friday, November 7th. Peel Hunt reiterated an “add” rating and set a GBX 270 price objective on shares of ConvaTec Group in a research report on Thursday, November 13th. Finally, Berenberg Bank lifted their price target on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research report on Thursday, January 22nd.

ConvaTec Group Stock Performance

Shares of CTEC stock opened at GBX 231.80 on Friday. ConvaTec Group has a 12-month low of GBX 209.40 and a 12-month high of GBX 311.20. The company has a market cap of £4.52 billion, a price-to-earnings ratio of 21.87, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The stock has a 50 day simple moving average of GBX 234.38 and a 200-day simple moving average of GBX 235.45. The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.